Product Overview
R3TA is supplied as a laboratory research material with clear product identification and storage guidance.
R3TA is a synthetic peptide-based research material supplied by Pure BioLabs for controlled laboratory research and scientific investigation.
Research Information
This material is supplied for laboratory research and analytical investigation. It is not supplied as a medicine, dietary supplement or therapeutic product.
Not for human or veterinary consumption.
R3TA Research Overview
R3TA is a triple hormone-receptor research compound that has been investigated in clinical and preclinical research relating to metabolic regulation, body weight, glucose homeostasis and energy metabolism.
Triple-Receptor Signalling
- Research has investigated simultaneous GIP, GLP-1 and glucagon receptor activity.
- These signalling pathways are involved in regulation of energy balance and metabolism.
- The combined mechanism distinguishes this compound from single- and dual-receptor research compounds.
Body-Weight Research
- Clinical research has investigated changes in body weight over extended treatment periods.
- The Phase 2 study reported substantial weight reduction compared with placebo.
- Later Phase 3 research has continued to investigate longer-term weight outcomes.
Metabolic Research
- Research has examined glucose and insulin-related metabolic parameters.
- Studies have investigated changes in waist circumference and other metabolic measures.
- Ongoing clinical research continues to evaluate metabolic outcomes.
Glucose & Energy Homeostasis
- The receptor pathways investigated with R3TA are involved in glucose and energy regulation.
- Clinical studies have measured changes in glucose-related parameters.
- Research continues to investigate the interaction between these pathways and energy homeostasis.
Clinical Research
- Phase 2 research evaluated the compound in adults with obesity or overweight with a weight-related condition.
- Phase 2 results included 48-week body-weight outcomes.
- Phase 3 research has subsequently investigated longer treatment periods and additional metabolic outcomes.
Safety Research
- Clinical trials have included formal safety monitoring.
- Gastrointestinal adverse events were among the commonly reported events in Phase 2 research.
- Continued clinical development is evaluating the safety profile over longer periods.
Selected Clinical Research Findings
Mean body-weight reduction reported at 48 weeks in the 12 mg study group.
Mean body-weight reduction reported at 80 weeks in the 12 mg TRIUMPH-1 group.
Research Context
The clinical findings presented above are results from published or reported clinical research and should not be interpreted as claims about Pure BioLabs products. R3TA is supplied by Pure BioLabs strictly as a laboratory research material and is not supplied as an approved medicine or treatment.
Product Specifications
Storage
Store according to the storage conditions supplied with the product and keep the vial sealed when not in use.
Certificate of Analysis
Certificate of Analysis documentation can be provided where applicable to the relevant product batch.
Important Information
Pure BioLabs products are supplied strictly as laboratory research materials. They are not intended for human or veterinary use, diagnosis, treatment, prevention or cure of any disease or condition.
Not for human consumption. Not for veterinary consumption.